NEXTCURE INC. news, videos and press releases
For more news please use our advanced search feature.
NEXTCURE INC. - More news...
NEXTCURE INC. - More news...
- NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
- NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
- NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
- NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
- NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
- NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
- NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
- NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
- NextCure Provides Business Update and Reports Full Year 2023 Financial Results
- NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
- NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
- NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
- NextCure Provides Year-End Clinical Pipeline Updates
- NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
- NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
- NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
- Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
- NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
- A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
- NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
- Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
- NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
- NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
- NextCure to Present at the JMP Securities Life Sciences Conference
- NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
- NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
